Wang, Lu
Luan, Yingcai
Jia, Chuandong
Xie, Xin
Zhang, Zihao
Xie, Xiaochuan
Wang, Qian
Hu, Chanyan
Xie, Fang
Abdel-Moneim, Mohamed
Hovsepian, Lionel
Zhao, Zhihong
Yang, Na
Hou, Jie
Funding for this research was provided by:
Sanofi
Article History
Accepted: 4 September 2022
First Online: 27 November 2022
Declarations
:
: This study was sponsored by Sanofi.
: Xiaochuan Xie, Qian Wang, Chanyan Hu, Fang Xie, Mohamed Abdel-Moneim, Lionel Hovsepian, Zhihong Zhao, and Na Yang are employees of Sanofi, and they may hold shares and/or stock options in the company. The other authors have no conflicts of interest.
: Conceptualization: J.H., L.W., Y.L., X.X., C.H., and F.X. Data acquisition: C.J., X.X., and Z.Z.. Data analysis or interpretation: J.H., L.W., Y.L., X.X., Q.W., C.H., F.X., M.A.-M., L.H., Z.Z., and N.Y. Drafting: X.X., J.H., L.W., and Y.L. Critical revision: J.H., L.W., Y.L., C.J., X.X., Z.Z., X.X., Q.W., C.H., F.X., M.A.-M., L.H., Z.Z., and N.Y. Final approval: J.H., L.W., Y.L., C.J., X.X., Z.Z., X.X., Q.W., C.H., F.X., M.A.-M., L.H., Z.Z., and N.Y.
: The study was conducted in accordance with 1964 Declaration of Helsinki and its latest amendments, good clinical practice guidelines, and other local regulatory laws and guidelines (clinical study number CTR20202332). The study was approved by the Clinical Trial Ethics Committee of Peking University.
: Written informed consent was obtained from all eligible participants before induction.
: Not applicable.
: Not applicable.
: Not applicable.